vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and SES AI Corp (SES). Click either name above to swap in a different company.
SES AI Corp is the larger business by last-quarter revenue ($4.6M vs $2.5M, roughly 1.8× Bolt Biotherapeutics, Inc.). Bolt Biotherapeutics, Inc. runs the higher net margin — -265.2% vs -373.5%, a 108.2% gap on every dollar of revenue.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
SES S.A. is a Luxembourgish communications satellite operator supplying video and data connectivity worldwide to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions.
BOLT vs SES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $4.6M |
| Net Profit | $-6.6M | $-17.0M |
| Gross Margin | — | 11.3% |
| Operating Margin | -283.4% | -387.7% |
| Net Margin | -265.2% | -373.5% |
| Revenue YoY | — | — |
| Net Profit YoY | 58.4% | 50.7% |
| EPS (diluted) | $-9.38 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $4.6M | ||
| Q3 25 | $2.2M | $7.1M | ||
| Q2 25 | $1.8M | $3.5M | ||
| Q1 25 | $1.2M | $5.8M | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $-6.6M | $-17.0M | ||
| Q3 25 | $-7.1M | $-20.9M | ||
| Q2 25 | $-8.6M | $-22.7M | ||
| Q1 25 | $-11.0M | $-12.4M | ||
| Q4 24 | $-15.9M | — | ||
| Q3 24 | $-15.2M | — | ||
| Q2 24 | $-21.2M | — | ||
| Q1 24 | $-10.8M | — |
| Q4 25 | — | 11.3% | ||
| Q3 25 | — | 51.1% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -283.4% | -387.7% | ||
| Q3 25 | -355.1% | -262.0% | ||
| Q2 25 | -510.5% | -652.3% | ||
| Q1 25 | -991.4% | -401.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1441.1% | — | ||
| Q2 24 | -1772.3% | — | ||
| Q1 24 | -324.1% | — |
| Q4 25 | -265.2% | -373.5% | ||
| Q3 25 | -329.4% | -293.9% | ||
| Q2 25 | -474.6% | -642.2% | ||
| Q1 25 | -903.4% | -214.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1330.1% | — | ||
| Q2 24 | -1662.4% | — | ||
| Q1 24 | -205.0% | — |
| Q4 25 | $-9.38 | $-0.05 | ||
| Q3 25 | $-3.72 | $-0.06 | ||
| Q2 25 | $-4.46 | $-0.07 | ||
| Q1 25 | $-0.29 | $-0.04 | ||
| Q4 24 | $-13.73 | — | ||
| Q3 24 | $-7.93 | — | ||
| Q2 24 | $-11.12 | — | ||
| Q1 24 | $-0.28 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $29.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $214.8M |
| Total Assets | $56.7M | $272.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $29.5M | ||
| Q3 25 | $31.9M | $35.3M | ||
| Q2 25 | $34.8M | $11.8M | ||
| Q1 25 | $38.8M | $56.1M | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | — |
| Q4 25 | $26.5M | $214.8M | ||
| Q3 25 | $32.1M | $228.2M | ||
| Q2 25 | $38.8M | $249.2M | ||
| Q1 25 | $46.8M | $269.9M | ||
| Q4 24 | $57.2M | — | ||
| Q3 24 | $72.0M | — | ||
| Q2 24 | $85.9M | — | ||
| Q1 24 | $104.2M | — |
| Q4 25 | $56.7M | $272.6M | ||
| Q3 25 | $65.1M | $288.8M | ||
| Q2 25 | $75.5M | $290.5M | ||
| Q1 25 | $85.9M | $306.0M | ||
| Q4 24 | $99.6M | — | ||
| Q3 24 | $109.3M | — | ||
| Q2 24 | $124.2M | — | ||
| Q1 24 | $142.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-10.4M |
| Free Cash FlowOCF − Capex | — | $-11.1M |
| FCF MarginFCF / Revenue | — | -243.7% |
| Capex IntensityCapex / Revenue | — | 15.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-61.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-10.4M | ||
| Q3 25 | $-9.7M | $-14.3M | ||
| Q2 25 | $-9.6M | $-10.8M | ||
| Q1 25 | $-13.4M | $-22.8M | ||
| Q4 24 | $-14.4M | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | $-16.1M | — | ||
| Q1 24 | $-16.8M | — |
| Q4 25 | — | $-11.1M | ||
| Q3 25 | — | $-14.7M | ||
| Q2 25 | — | $-11.6M | ||
| Q1 25 | — | $-23.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -243.7% | ||
| Q3 25 | — | -206.9% | ||
| Q2 25 | — | -329.6% | ||
| Q1 25 | — | -410.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 15.6% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 22.8% | ||
| Q1 25 | — | 15.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
